These complementary therapeutic strategies—activating WHSC1 to reinforce antigen presentation and inhibiting PRMT1 to lift epigenetic repression—offer a dual-pronged approach to enhance tumor immunogenicity. Here, PRMT1 is linked to neoplasm.